A balloon catheter system for infusion of micelles at high pressure. The system includes a catheter with a drug eluting balloon with a perforated wall with numerous pores, a reservoir of nanoparticles in an aqueous solution disposed within the balloon or in fluid communication with the balloon. The particles may comprise drug loaded micelles, where the micelles are provided in the size range of 40 to 250 nm generally (0.040 μm to 0.250 μm), and the pores of the balloon wall are configured to allow passage of the micelles with a minimum of disruption, The pores are conical, with the diameter of the pore at the inside of the balloon wall smaller than the diameter of the pores at the outside of the balloon wall.

The invention provides liquid injectable copolymers of TMC and HTMC that are degradable in vivo. Degradation can be tailored by adjusting the amount of HTMC in the copolymer, the initial molecular weight of the copolymer, and the characteristics of the initiator used in its preparation. Specifically, the degradation rate increases as the amount of HTMC incorporated into the copolymer increases, as the molecular weight of the copolymer decreases, and as the hydrophobicity of the initiator decreases. Moreover, the degradation yields products such as glycerol and carbon dioxide that are non-toxic in vivo, and which will not cause a substantive change in tissue pH upon implantation in vivo. The copolymers may be used in applications such as drug delivery and as coatings.

The present invention is directed to an absorbable hemostatic patch that utilizes a biocompatible fibrous, fabric substrate that is melt-blown and napped or loosened at the surface, with the substrate having a low-profile, high flexibility, strength and porosity that is suitable for coating cross-linkable active molecules and ultimately effective for use as a hemostat in situations of problematic bleeding.

A tubular nonwoven structure as an active agent carrier (“sleeve”) for the atraumatic treatment of hollow organs, in particular applicable via a balloon catheter, as well as a method for the production thereof, wherein the sleeve is folded about a longitudinal sleeve axis in an initial state and is unfoldable in a final state for attachment to an inner wall of a hollow organ, the tubular sleeve is formed of first biodegradable polymer nanofibers and the folding of the sleeve is directed as pleating about a longitudinal sleeve axis, a medicinal active agent is incorporated into the first polymer nanofibers and/or is arranged in interspaces between the polymer nanofibers, and the first polymer fibers are formed such that the polymer fibers degrade over a period of 2 weeks to 3 months so that the active agent can be delivered to a hollow organ wall in this period of time.

Drug delivery systems and wearable articles including the drug delivery systems are provided. The drug delivery systems may include a substrate coated with at least one polymer and at least one active compound. The substrate is operable to include yarns, yarn precursors, threads, filaments, fibers, and/or other suitable substrates. Methods for manufacturing drug delivery systems are also provided. The methods are operable to include disposing a solution including a monomer and an active compound on the substrate. The methods are also operable to include exposing the solution and the substrate to UV light to initiate polymerization of the solution.

Disclosed are nasal dressings and nasal stents comprising a collagen foam. Also disclosed are methods of making and using such nasal dressings and nasal stents. In an embodiment, a nasal dressing or nasal stent is formed by a method comprising the steps of: forming an aqueous mixture of from 5 to 25 wt % of acid-soluble collagen and from 75 to 95 wt % of collagen fibers, both based on the total solids content of the aqueous mixture, placing the aqueous mixture into a mold, freeze-drying the aqueous mixture while in the mold, thereby forming a collagen foam, and cross-linking the collagen foam.

Disclosed are devices and methods for improving healing of an enthesis. An effective amount of a composition comprising one or more sex steroids and/or sex steroid equivalents is locally administered at the site of a repaired enthesis. The composition causes upregulation of one or more chondrogenic, angiogenic, and/or tendon modulation genes, resulting in improved healing of the enthesis. The improved enthesis healing occurs even where the subject has normal levels of sex hormones.

The present invention relates to the use of scaffolds to enhance the viability of cells implanted in the integumentary system such that the cell may release an agent. The scaffold is capable of protecting the cell, as well as allowing for adequate nutrient delivery at the implant site through vascularisation in and around the scaffold.

Methods for manufacturing drug delivery systems are provided. The drug delivery systems may include a substrate coated with at least one polymer and at least one active compound. The substrate may include yarns, yarn precursors, threads, filaments, fibers, and/or other suitable substrates. The methods may include disposing a solution including a monomer and an active compound on the substrate. The methods may also include exposing the solution and the substrate to UV light to initiate polymerization of the solution.

Transcervical access systems for providing transcervical movement of fluids are described. The transcervical access systems are effective for transferring a broad range of fluids, including the delivery of hydrogel precursors, saline, and imaging fluids, to the uterine cavity. The transcervical access systems are also effective for removing fluids from the uterine cavity, such as residual bodily fluids, residual fluids from a procedure, or tissue. The transcervical access systems described include flow limiters, such as egress limiters and/or cervical plugs. Methods of use of the transcervical access systems are also described. Methods include using the transcervical access systems to transcervical access the uterine cavity and install hydrogel. The transcervical access systems and associated methods can be useful for providing degradable hydrogel in the uterine cavity, including the cervical canal, for the prevention of adhesions following intrauterine procedures.